摘要: Bagsvrd, Denmark, 2 September 2014 – Novo Nordisk today announced a decisionto discontinue all its research and development (RD) activities within inflammatorydisorders while increasing its efforts w ...
| Bagsværd, Denmark, 2 September 2014 – Novo Nordisk today announced a decision to discontinue all its research and development (R&D) activities within inflammatory disorders while increasing its efforts within diabetes prevention and treatment, obesity and diabetes complications. The decision to discontinue all R&D within inflammatory disorders follows a review of Novo Nordisk’s strategic position in the therapeutic area after the recently announced discontinuation of the company’s most advanced compound, anti-IL-20 for the treatment of rheumatoid arthritis. “The discontinuation of anti-IL-20 delays our earliest possible entrance into the market for anti-inflammatory therapeutics to the late 2020s,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. He continues: “Significant unmet opportunities remain within diabetes, including prevention, obesity and diabetes complications. We have therefore decided to further increase our R&D efforts within diabetes which is our main business area.” The decision will directly impact approximately 400 employees. Novo Nordisk currently estimates that it will be possible to offer other positions within the company to more than half of the affected employees. The company has initiated negotiations with the relevant local unions regarding redundancy plans. Novo Nordisk expects that all ongoing clinical activities within inflammatory disorders will be finalised within the coming 6 months. After closure of the clinical trials, patients will be followed in accordance with the protocol and further treatment will be the responsibility of their doctors and according to local practices. Financial implications As a consequence of the discontinuation of all R&D activities within inflammatory disorders, the company expects to incur a non-recurring cost of around 700 million Danish kroner in 2014. Of this around 400 million Danish kroner relates to impairment of intangible assets, and around 300 million Danish kroner relates to other exit costs such as project closures and severance payments. |
我们提供专业的服务， 从产品定位、机械的生产制造，我们 实力出众，只因我们更努力
公司生产的生物反应器及各种配套设备，可替代国外同类产品的垄断，并帮助企业节省生产成本，同时提供生产过程中各种技术支持。
我们一如既往地根据用户的需求、市场环境、企业状况等进行综合分析并提供真实可靠的解决方案，迄今为止服务上千家企业。
我们将致力于优质的技术服务确保每个机械设备的安全，用更成熟的方案解决每一个问题，为企业提供一站式服务。
